Bal Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.7 pts less than Nifty Microcap 250 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bal Pharma Limited reported standalone revenue from operations of Rs. 31,079.70 lakhs for FY26, up 2.7% from Rs. 30,249.64 lakhs in FY25. However, standalone net profit declined 13.4% to Rs. 675.12 lakhs from Rs. 779.95 lakhs, while EPS dropped to Rs. 4.51 from Rs. 4.89. Consolidated revenue was Rs. 31,166.13 lakhs with consolidated net profit of Rs. 632.00 lakhs (down 12.7% YoY). The auditors issued an unmodified (clean) opinion. The board recommended a dividend of Rs. 1.20 per share (12%). Other key approvals include a preferential issue of 10 lakh warrants to promoters and grant of 5 lakh stock options to employees under the ESOP plan 2025.
The stock may see neutral reaction as revenue growth is modest and PAT declined despite positive operating cash flows. The preferential warrant issue to promoters indicates potential dilution. The clean audit and dividend announcement provide some support.